Alzinova AB (publ) (ALZ.ST)

SEK 3.5

(0.0%)

Market Cap (In SEK)

312.07 Million

Revenue (In SEK)

270 Thousand

Net Income (In SEK)

-16.48 Million

Avg. Volume

646.95 Thousand

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.949266-4.62
PE
-
EPS
-
Beta Value
1.229
ISIN
SE0007413455
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Carol Routledge
Employee Count
-
Website
https://www.alzinova.com
Ipo Date
2015-11-25
Details
Alzinova AB (publ), a biopharma company, engages in the development of an active immunotherapy for the treatment of Alzheimer's disease in Sweden. Its lead candidate is ALZ-101, an oligomer-specific vaccine for the treatment of Alzheimer's disease; and ALZ-201, a monoclonal antibody that is used for the treatment of toxic Aß oligomers. The company was founded in 2011 and is based in Mölndal, Sweden.